Abstract: The lyophilized formulation of stem cell-derived exosomes and the anti-inflammatory composition including the same as an active ingredient is able to stabilize stem cell-derived exosomes and exhibit excellent anti-inflammatory effects, and particularly, exhibit remarkable anti-inflammatory effects as compared with not-lyophilized stem cell-derived exosomes isolated and purified from conditioned media of stem cells. Therefore, the lyophilized formulation of stem cell-derived exosomes and the anti-inflammatory composition including the same as an active ingredient is able to effectively prevent, suppress, alleviate, ameliorate or treat inflammatory response or inflammatory diseases.

Abstract: A method to grow cannabis is described, wherein the method includes providing and treating a source of water, mixing the water with an additive to form a liquid mixture, transferring the liquid mixture to a plurality of cannabis plants grown in a growing medium including a mycorrhiza fungus, and growing the cannabis using a humidity control method, then harvesting the cannabis plants. Trimming and grinding the cannabis along with use of environmental control methods including temperature, humidity, lighting schedules, and carbon dioxide concentrations are also described.

Abstract: The present invention relates to a method of treating acute or chronic systemic graft-versus-host disease (GVHD) with extracellular vesicles, e.g., exosomes obtained from human cardiospheres or cardiosphere-derived cells (CDCs), wherein systemic GVHD involves, e.g., at least two organs selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, genitalia, and eyes. The present invention also provides a pharmaceutical formulation comprising extracellular vesicles, e.g., exosomes obtained from human cardiospheres or CDCs, for systemic administration, e.g., intravenous infusion, to a human subject in need of treatment of systemic GVHD.

Abstract: The present invention provides a topical composition comprising extract from Coriolus versicolor for use for preventing and/or treating by vaginal or cervical administration of a vaginal or cervical disorder which is caused by an infectious agent, in particular, human papiloma virus infections and related disorders, including cervical cancer. The composition of the invention acts enhancing genital immunity against infectious agents and re-epithelising damaged tissue.

Abstract: Present invention discloses an oil palm composition for use in prevention or treatment of Alzheimer's disease. The composition is useful in impeding formation of neurotoxic peptide. Present invention can be used in preparation of a medicament in a therapeutic effective amount for prevention or treatment of Alzheimer's disease and diseases related thereto.

Abstract: A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

Abstract: The present invention relates to a method of treating meningioma including administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising Coptis chinensis, Phellodendron amurense, Glycyrrhiza uralensis, Atractylodes lancea, Artemisia carvifolia, Anemarrhena asphodeloides, and Cortex Lycii.

Abstract: The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.

Abstract: Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.

Abstract: Disclosed is a new drug application of a Pithecellobium clypearia Benth Extract (EA), and particularly is a method of the EA used for treating multiple diseases caused by drug resistant bacteria infection. Related drug resistant bacteria include a Multi-Drug Resistant (MDR) Acinetobacter baumannii (MDRAB), an MDR Pseudomonas aeruginosa (MDRPA), an Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (ECO) and an ESBL-producing Klebsiella pneumonia (KPN).

Abstract: The invention relates to a method for obtaining the water-insoluble fraction of Carica papaya sap, enriched with Carica papaya lipase, the water-insoluble fraction obtainable by this method, a method for the preparation of an activated fat and/or an activated wax by means of said water-insoluble fraction of the Carica papaya sap, the activated fat and/or the activated wax capable of being obtained by this method, a composition combining said activated fat and/or said activated wax, as well as the cosmetic use of these products.

Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.

Abstract: Compositions and methods are presented that substantially increase levels of BDNF in blood, and even more pronouncedly exosomal BDNF levels. Suitable compositions include whole coffee fruit extracts and powders that are orally administered at relatively low dosages.

Abstract: The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.

Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.

Abstract: The invention relates to a soybean seed extract, method for producing the same and uses of the extract of soybean seeds in promoting wound healing, promoting neuron cell proliferation and/or treating brain diseases and/or neurodegenerative diseases, treating breast cancer, reducing side effects of interfering with DNA and/or RNA replication drugs and/or enhancing pharmaceutical effects of interfering with DNA and/or RNA replication drugs.

Abstract: A composition, a health functional food or a treatment method of the present invention has a remarkable cranial nerve cell protection effect and simultaneously has a sensorimotor function recovery promotion effect and a body weight increasing effect. Accordingly, the present invention has effects of preventing stroke or neurodegenerative diseases, protecting cranial nerve cell cells over the mid to long term immediately after the onset of disease, promoting the recovery of a sensorimotor function reduced by stroke and neurodegenerative diseases, and increasing a reduced body weight. Therefore, the present invention can be used for effectively preventing, treating or managing stroke and neurodegenerative diseases.

Abstract: The present invention relates to the use of an Angiotensin II type 1 (AT1) receptor blocker for promoting sleep and/or the treatment of insomnia. It is based, at least in part, on the results of experiments performed using a validated rat model of stress-induced insomnia in which candesartan was found to ameliorate sleep disturbances induced by stress. Further, it was observed that this effect seems to be caused by blockade of AT1 receptors located in several brain regions that are key components of the neural circuitry activated during insomnia. In contrast to currently marketed treatments for insomnia, the AT1 receptor blocker was found to restore normal sleep without inhibiting REM sleep and/or inducing atypical wave components in the EEG.

Abstract: A method for decreasing proliferation of cancer cells comprises the steps of administering a sensitizer. Sensitizers can include selenium, fish oil, and a combination of selenium and fish oil to a cancer cell. The method contemplates that the selenium and fish oil are administered in an amount effective to respectively increase the sensitivity of the cancer cells, and the administration of the combination of selenium and fish oil are administered in an amount effective to synergistically increase the sensitivity of the cancer cells more than the selenium or the fish oil alone. The method additionally exposes cancer cells to temperatures in excess of 37° C.

Abstract: The invention relates to the Proline-Rich Polypeptide complex (PRP) derived from the mammalian colostrum for use in the treatment of the disorders and conditions related to the alterations of the Brain-Derived Neurotrophic Factor level as well as modulation thereof, particularly disorders and conditions wherein therapeutic strategy is based on the increasing of the BDNF concentration in blood. The PRP complex is postulated to be used for nutrition of adults, young children/babies and infants to promote and preserve the proper development and function of both immune and nervous system. PRPs may be used for supplementation of modified milk and infant milk formulae to make it closer to breast milk.